Esophagitis Clinical Trial
Official title:
Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia
This is a prospective descriptive cross sectional study to determine the percentage of patients presenting with dysphagia who are found to have eosinophilic esophagitis (EoE) and to establish which presenting factors warrant esophageal biopsies. We hypothesize that a greater than expected percentage of patients who are biopsies will have histologic changes consistent with EE.
All patients presenting with dysphagia who do not already carry a previous diagnosis for their dysphagia will be asked to enroll. If patients have undergone previous work up for dysphagia such as manometry, 24-hour probe, or barium swallow they can still participate in this study. Informed consent will take place prior to enrollment. After patients present with dysphagia they will fill-out a questionnaire regarding their dysphagia symptoms. An EGD with biopsies will then be performed. Biopsies will be taken from 4 quadrants in the proximal and distal esophagus. The distal esophagus biopsies will be taken 5 cm proximal to the Z-line. Proximal biopsies will be taken anywhere proximal to 30 cm from the incisors. ;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
| Recruiting |
NCT05326113 -
The Effect of Physiotherapy on Post POEM Reflux
|
N/A | |
| Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
| Terminated |
NCT02575391 -
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00123630 -
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
|
Phase 2 | |
| Completed |
NCT00081315 -
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00471094 -
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
|
Phase 2 | |
| Completed |
NCT00579410 -
Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
|
N/A | |
| Recruiting |
NCT05109819 -
Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression.
|
N/A | |
| Withdrawn |
NCT01824199 -
CYP2C19 Genotype Predictor of Gastric Acid Suppression
|
Early Phase 1 | |
| Completed |
NCT01556919 -
Esophageal Monitoring Device for Assessing Mucosal Impedance
|
||
| Active, not recruiting |
NCT03835663 -
The Bacterial Composition of the Stomach in Reflux Disease
|
||
| Completed |
NCT00195208 -
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
|
Phase 3 | |
| Completed |
NCT00175045 -
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
|
Phase 2 | |
| Completed |
NCT05129670 -
Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum
|
N/A | |
| Recruiting |
NCT05004155 -
Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
|
||
| Completed |
NCT03228147 -
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
|
N/A | |
| Completed |
NCT00133770 -
Intravenous (IV) Pantoprazole in Erosive Esophagitis
|
Phase 4 | |
| Completed |
NCT01322633 -
Risk of Cancer Among Pantoprazole Users
|
N/A |